PGR and breast cancer: Our data showed that miR‐4732‐5p expression showed no significant difference among the four molecular subtypes (Luminal A, Luminal B, HER2‐enriched and Triple negative) (Figure S1A, P > 0.05), or between ER+ and ER‐ (Figure S1B, P > 0.05), or PR+ and PR‐ (Figure S1C, P > 0.05), or HER2+ and HER2‐ (Figure S1D, P > 0.05) breast cancers.